NCT03365999View on ClinicalTrials.gov

Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 15, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Knee OsteoarthritisBlood ClotTransfusion Related ComplicationBlood Loss
Interventions
DRUG

Oral Tranexamic Acid

Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).

DRUG

Oral Aminocaproic Acid

Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).

Trial Locations (1)

1-4469

Facultad de Medicina UANL, Monterrey

All Listed Sponsors
lead

Universidad Autonoma de Nuevo Leon

OTHER

NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. | Biotech Hunter | Biotech Hunter